Travere Therapeutics Inc (NASDAQ:TVTX) currently has a daily average trading volume of 1.29M but it saw 1877212 shares traded in last market. With a market cap of 1.69B USD, the company’s current market price of $19.46 remained unchanged while comparing to the previous closing price of $19.46. In past 52 weeks, the stock remained buoying in the range of price level as high as $20.33 and as low as $5.12. In the recent trading on the day, stock has struck highest price mark of $18.535 while lowest mark touched by it was $19.69.
Taking a look at 20-day trading activity of Travere Therapeutics Inc (TVTX) gives us an average price of $18.17, while its current price level is -4.28% below from 52-week high level whereas it is 280.08% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $18.29 while that of 200 days or SMA-200 reads an average of $12.18. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.96% during that period while stretching the period over a month that increases to 5.04%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 59.31 which implies that the stock is in neutral territory.
Wells Fargo upgraded its recommendation for the stock as a “Overweight” from “Equal Weight” on October 21, 2024 while assigning a price target range of $9-$27.
Over the week, TVTX’s stock price is moving 14.00% up while it is 15.42% when we observe its performance for the past one month. Year-to-date it is 11.71% up and over the past year, the stock is showing an upside performance of 122.65%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of -0.38 while estimate for next year EPS is -2.84. In next quarter, company is expected to be making quarterly sales of $72.92M as analysts are expecting the sales for current fiscal year at $230.15M and seeing the company making $340.2M in sales next year. Moreover, analysts are in estimates of $70.96M for current-quarter revenue.
Currently, Travere Therapeutics Inc’s total number of outstanding shares is 87.03M with 0.65% of that held by the insiders while 98.01% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -117.93% and return on equity (ROE) at -279.94%. Stock’s beta reads 0.72. Stock has a price to sale or P/S ratio amounts to 8.32. Its return on asset (ROA) is -52.19% on average.
